MX2018013507A - Composiciones y metodos para el tratamiento de la inflamacion o infeccion del ojo. - Google Patents

Composiciones y metodos para el tratamiento de la inflamacion o infeccion del ojo.

Info

Publication number
MX2018013507A
MX2018013507A MX2018013507A MX2018013507A MX2018013507A MX 2018013507 A MX2018013507 A MX 2018013507A MX 2018013507 A MX2018013507 A MX 2018013507A MX 2018013507 A MX2018013507 A MX 2018013507A MX 2018013507 A MX2018013507 A MX 2018013507A
Authority
MX
Mexico
Prior art keywords
eye
compositions
methods
inflammation
infection
Prior art date
Application number
MX2018013507A
Other languages
English (en)
Inventor
Capriotti Joseph
Capriotti Kara
pelletier Jesse
Original Assignee
Veloce Biopharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veloce Biopharma Llc filed Critical Veloce Biopharma Llc
Publication of MX2018013507A publication Critical patent/MX2018013507A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79—Polymers of vinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Se exponen y describen composiciones y métodos para prevenir, tratar o mejorar una afección o trastorno del ojo o área que rodea al ojo.
MX2018013507A 2016-05-05 2017-05-05 Composiciones y metodos para el tratamiento de la inflamacion o infeccion del ojo. MX2018013507A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662332306P 2016-05-05 2016-05-05
PCT/US2017/031390 WO2017193060A1 (en) 2016-05-05 2017-05-05 Compositions and methods for treatment of inflammation or infection of the eye

Publications (1)

Publication Number Publication Date
MX2018013507A true MX2018013507A (es) 2019-09-11

Family

ID=60203517

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013507A MX2018013507A (es) 2016-05-05 2017-05-05 Composiciones y metodos para el tratamiento de la inflamacion o infeccion del ojo.

Country Status (10)

Country Link
US (1) US20190160003A1 (es)
EP (1) EP3452015A4 (es)
KR (1) KR20190005179A (es)
CN (1) CN109475496A (es)
BR (1) BR112018072664A2 (es)
CA (1) CA3023259A1 (es)
MX (1) MX2018013507A (es)
PH (1) PH12018502318A1 (es)
SG (1) SG11201809811VA (es)
WO (1) WO2017193060A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019099055A1 (en) * 2017-11-20 2019-05-23 Veloce Biopharma, Llc Novel ophthalmic composition and methods of use
WO2019135779A1 (en) * 2018-01-08 2019-07-11 Veloce Biopharma, Llc Novel ophthalmic composition and methods of use
NL2025641B1 (en) * 2020-04-17 2023-06-22 Veloce Biopharma Llc Methods and compositions for improved treatment of sinus disease
CN114216993B (zh) * 2021-12-27 2024-01-23 诺峰药业(成都)有限公司 一种醋酸泼尼松龙滴眼液有关物质的检测方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5556848A (en) * 1993-12-27 1996-09-17 Senju Pharmaceutical Co., Ltd. Ophthalmic suspension containing diflupredonate
US20050095205A1 (en) * 2003-10-31 2005-05-05 Ramesh Krishnamoorthy Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
US7767217B2 (en) * 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
US20110319805A1 (en) * 2010-06-29 2011-12-29 Bryan Knicely Morris Topical composition for treating the skin
WO2012155062A1 (en) * 2011-05-12 2012-11-15 Foresight Biotherapeutics, Inc. Stable povidone-iodine compositions with steroids or non-steroidal anti-inflammatories
GB201114725D0 (en) * 2011-08-25 2011-10-12 Altacor Ltd Ophthalmic formulations
US20140273525A1 (en) * 2013-03-13 2014-09-18 Intermolecular, Inc. Atomic Layer Deposition of Reduced-Leakage Post-Transition Metal Oxide Films
EP3016634A2 (en) * 2013-07-05 2016-05-11 Therakine Biodelivery GmbH Drug-delivery composition for topical applications and injections and ophtalmic formulations, method for manufacturing thereof, and methods for delivery a drug-delivery composition

Also Published As

Publication number Publication date
US20190160003A1 (en) 2019-05-30
CN109475496A (zh) 2019-03-15
KR20190005179A (ko) 2019-01-15
BR112018072664A2 (pt) 2019-02-19
SG11201809811VA (en) 2018-12-28
CA3023259A1 (en) 2017-11-09
EP3452015A1 (en) 2019-03-13
EP3452015A4 (en) 2019-12-11
WO2017193060A1 (en) 2017-11-09
PH12018502318A1 (en) 2019-04-15

Similar Documents

Publication Publication Date Title
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
MX2023003461A (es) Tratamiento de infeccion por clostridium difficile.
MX2019007030A (es) Composiciones y metodos para el tratamiento del cancer.
MX2019003938A (es) Compuestos espirociclicos.
MX2018003472A (es) Moduladores de la expresion de kras.
SG10201901010PA (en) Combination therapy for treating a paramyxovirus
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MD3209310T2 (ro) Compoziții care conțin tulpini bacteriene
MD3209381T2 (ro) Compoziții care conțin tulpini bacteriene
GB2541571A (en) Pharmaceutical compositions
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
PH12018502318A1 (en) Compositions and methods for treatment of inflammation of infection of the eye
MX2020005567A (es) Metodos de tratamiento con asparaginasa.
MX2019001718A (es) Fracciones de plasma sanguineo como tratamiento para trastornos cognitivos asociados con el envejecimiento.
PH12018502020A1 (en) Methods for treating and preventing c. difficile infection
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
MX2020004666A (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
PH12018502154A1 (en) Methods of treating ocular conditions
MX2017012553A (es) Compuestos espirociclicos.
PH12019502174A1 (en) Modulators of pcsk9 expression
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
MX2017014436A (es) Compuestos biciclicos.
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
WO2015142865A3 (en) Metakaryocidal treatments